Why the FDA’s approval of revolutionary sickle cell gene therapy is a ‘big deal’

Sickle cell disease is a chronic, debilitating condition that affects nearly 100,000 Americans, most of them with African ancestry. Now, the FDA has approved a groundbreaking treatment for it that uses the gene-editing tool CRISPR. John Yang speaks with Yale School of Medicine assistant professor Dr. Cece Calhoun and New York Times reporter Gina Kolata to learn more. Stream your PBS favorites with the PBS app:  Find more from PBS NewsHour at  Subscribe to our YouTube channel:  Follow us: Facebook:  Twitter:  Instagram:  Subscribe: PBS NewsHour podcasts:  Newsletters: